BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Lupin Ltd. delivered in-line Q2 FY21 results.
The Ebitda margin has been on an uptrend since hitting all-time lows in Q3 FY20, led by cost rationalisation, better-than-industry growth in domestic formulations, and improved traction in the U.S., active pharmaceutical ingredient segment.
Near- to medium-term performance is expected to strengthen further on account of recently launched niche products and better operating leverage.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.